dehydroepiandrosterone and Atrophy studies

Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research Excerpts

Excerpt	Relevance	Reference
"Intravaginal dehydroepiandrosterone (DHEA) is a locally metabolised estrogen and androgen precursor, licensed in 2018 in the EU for moderate to severe vulvovaginal atrophy in postmenopausal women."	9.51	Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient? ( Bruce, D; Holloway, D; Kearley-Shiers, K, 2022)
"The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)."	9.27	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; BSc, AB; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2018)
"5 mg) dehydroepiandrosterone (DHEA, prasterone) for 12 weeks has shown clinically and statistically significant effects on moderate to severe (MS) dyspareunia as the most bothersome symptom (MBS), the present study analyzes the effect of a reduced dosing regimen on MBS vaginal dryness."	9.20	Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. ( Archer, DF; Ayotte, N; Balser, J; Bouchard, C; Cooper, TA; Côté, I; Elfassi, É; Grainger, DA; Koltun, W; Labrie, C; Labrie, F; Lavoie, L; Martel, C; Martens, M; Portman, DJ; Waldbaum, AS, 2015)
"The effects of intravaginal administration of dehydroepiandrosterone (DHEA) for the management of symptomatic vulvovaginal atrophy are reviewed."	8.91	Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. ( Archer, DF, 2015)
"Intravaginal dehydroepiandrosterone (DHEA) is a locally metabolised estrogen and androgen precursor, licensed in 2018 in the EU for moderate to severe vulvovaginal atrophy in postmenopausal women."	5.51	Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient? ( Bruce, D; Holloway, D; Kearley-Shiers, K, 2022)
"The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)."	5.27	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; BSc, AB; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2018)
"The objective of the study is to evaluate the acceptability of the intravaginal administration of ovules/suppositories of DHEA (dehydroepiandrosterone, prasterone) for the treatment of vulvovaginal atrophy (VVA) in women with moderate to severe dyspareunia who were administered daily for 12 weeks intravaginal 0."	5.22	Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. ( Archer, DF; Balser, J; Beauregard, A; Côté, I; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, E; Vaillancourt, M; Zerhouni, J, 2016)
"5 mg) dehydroepiandrosterone (DHEA, prasterone) for 12 weeks has shown clinically and statistically significant effects on moderate to severe (MS) dyspareunia as the most bothersome symptom (MBS), the present study analyzes the effect of a reduced dosing regimen on MBS vaginal dryness."	5.20	Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. ( Archer, DF; Ayotte, N; Balser, J; Bouchard, C; Cooper, TA; Côté, I; Elfassi, É; Grainger, DA; Koltun, W; Labrie, C; Labrie, F; Lavoie, L; Martel, C; Martens, M; Portman, DJ; Waldbaum, AS, 2015)
" estradiol, dehydroepiandrosterone [DHEA], progesterone) that causes menopause commonly affects a woman's general health and produces bothersome physical changes that may interfere with normal sexual and genitourinary functioning."	5.01	Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. ( Goldstein, SR; Kagan, R; Portman, DJ, 2019)
"The effects of intravaginal administration of dehydroepiandrosterone (DHEA) for the management of symptomatic vulvovaginal atrophy are reviewed."	4.91	Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. ( Archer, DF, 2015)
" The use of estrogen agonists/antagonists and intravaginal dehydroepiandrosterone (DHEA) have both been shown to positively affect vaginal atrophy symptoms without inducing endometrial proliferation."	4.86	Vulvovaginal atrophy: current and future therapies (CME). ( Ibe, C; Simon, JA, 2010)
" More recently, double-blind, placebo-controlled clinical trials have demonstrated that local vaginal dehydroepiandrosterone improves symptoms in postmenopausal women, including moderate to severe dyspareunia."	3.88	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. ( Archer, DF; Bachmann, G; Davis, SR; Goldstein, AT; Goldstein, I; Kellogg-Spadt, S; Kim, NN; Lowenstein, L; Nappi, RE; Pinkerton, JV; Simon, JA; Stuenkel, CA; Traish, AM; Vignozzi, L, 2018)
"Dehydroepiandrosterone (DHEA) applied on the dorsal skin of ovariectomized animals, at the twice daily dose of 30 mg, resulted in a complete reversal of the vaginal atrophy seen 1, 3 and 6 months after ovariectomy, and induced proliferation and mucification of the vaginal epithelium."	3.70	Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat. ( Bélanger, A; Flamand, M; Labrie, F; Sourla, A, 1998)
"We investigated the mechanism of dissociation of cortisol and dehydroepiandrosterone sulfate (DHEA-S) secretion by the adrenal glands after the removal of an adrenal gland containing an adrenocortical adenoma in a patient with Cushing's syndrome."	3.67	Mechanism of dissociation of cortisol and adrenal androgen secretion after removal of adrenocortical adenoma in patients with Cushing's syndrome. ( Higuchi, K; Ibayashi, H; Kato, K; Nawata, H; Takayanagi, R; Yanase, T, 1985)
"Dehydroepiandrosterone (DHEA) is a steroid hormone involved in physiological aging."	2.73	Effects of topical DHEA on aging skin: a pilot study. ( Baldo, F; Bastien, P; de Lacharriere, O; Nouveau, S, 2008)
" Vaginal estrogen preparations with the lowest systemic absorption rate may be preferred in women with history of breast cancer and severe vaginal atrophy."	2.48	Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. ( Bradshaw, K; Carr, BR; Tan, O, 2012)
" Given that the efficacy and long term safety of low dose vaginal estradiol and estriol therapy is well established and that vaginal estrogen requires application of 2-3 times a week, rather than daily dosing; the benefit of daily vaginal DHEA over estrogen also needs to be considered as women may find it unpalatable to adhere to daily dosing with a cream preparation."	2.47	Vaginal DHEA to treat menopause related atrophy: a review of the evidence. ( Davis, SR; Panjari, M, 2011)
" Therefore, the deleterious side-effects of chronic administration of GC emerges from both their direct catabolic activity and the suppression of DHEA production."	2.40	Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? ( Cutolo, M; Robinzon, B, 1999)
" Prasterone seems a safe and effective option to treat GSM in BCS receiving AIs."	1.72	Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. ( Alonso, I; Anglès-Acedo, S; Castelo-Branco, C; Castrejon, N; Cebrecos, I; Gómez, S; Matas, I; Mension, E; Ribera, L; Tortajada, M, 2022)

Research

Studies (46)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (4.35)	18.7374
1990's	4 (8.70)	18.2507
2000's	2 (4.35)	29.6817
2010's	29 (63.04)	24.3611
2020's	9 (19.57)	2.80

Authors	Studies
Stute, P	1
Bertschy, S	1
Birkhaeuser, M	1
Bitzer, J	1
Ging, A	1
Raggi, A	1
Steimann, S	1
Stute, V	1
Mension, E	1
Alonso, I	1
Cebrecos, I	1
Castrejon, N	1
Tortajada, M	1
Matas, I	1
Gómez, S	1
Ribera, L	1
Anglès-Acedo, S	1
Castelo-Branco, C	1
Kearley-Shiers, K	1
Holloway, D	1
Bruce, D	1
Salvatore, S	3
Benini, V	3
Ruffolo, AF	3
Degliuomini, RS	3
Redaelli, A	3
Casiraghi, A	3
Candiani, M	3
Cipriani, S	1
Maseroli, E	1
Ravelli, SA	1
Vignozzi, L	2
Gajarawala, SN	1
Wood, TA	1
Stanton, AP	1
Holton, M	1
Thorne, C	1
Goldstein, AT	2
Wang, J	1
Wang, L	1
Matarazzo, MG	1
Sarpietro, G	1
Fiorito, D	1
Di Pasqua, S	1
Ingrassano, S	1
Panella, MM	1
Cianci, A	1
Caruso, S	1
Pérez-López, FR	1
Phillips, N	2
Vieira-Baptista, P	1
Cohen-Sacher, B	1
Fialho, SCAV	1
Stockdale, CK	1
Labrie, F	15
Archer, DF	12
Martel, C	13
Vaillancourt, M	6
Montesino, M	6
Bachmann, G	2
Shifren, JL	1
Simon, JA	2
Goldstein, I	1
Kim, NN	1
Davis, SR	2
Kellogg-Spadt, S	1
Lowenstein, L	1
Pinkerton, JV	1
Stuenkel, CA	1
Traish, AM	1
Nappi, RE	1
Koltun, W	5
Vachon, A	2
Young, D	3
Frenette, L	2
Portman, D	2
Côté, I	7
Parent, J	2
Lavoie, L	8
BSc, AB	1
Balser, J	8
Moyneur, É	6
Portman, DJ	4
Goldstein, SR	1
Kagan, R	1
Heo, YA	1
Vegunta, S	1
Files, J	1
Kling, JM	1
Domoney, C	1
Bouchard, C	4
Elfassi, É	1
Grainger, DA	1
Ayotte, N	4
Cooper, TA	1
Martens, M	1
Waldbaum, AS	2
Labrie, C	3
Girard, G	3
Gallagher, JC	1
Cusan, L	4
Baron, M	2
Blouin, F	2
Beauregard, A	4
Wade, A	1
Dubé, R	2
Derogatis, L	1
Zerhouni, J	1
Ke, Y	1
Gonthier, R	1
Simard, JN	1
Pelletier, G	3
Bélanger, A	4
Utian, WH	1
Daniell, HW	1
Archer, D	1
Fortier, M	1
Gomez, JL	2
Moreau, M	1
Berger, L	1
Ibe, C	1
DeRogatis, LR	1
Panjari, M	1
Tan, O	1
Bradshaw, K	1
Carr, BR	2
Kushida, Y	1
Kumagai, S	1
Gotoh, K	1
Fujii, M	1
Touma, M	1
Hosono, M	1
Ikezoe, K	1
Nouveau, S	1
Bastien, P	1
Baldo, F	1
de Lacharriere, O	1
Parker, CR	1
Winkel, CA	1
Casey, ML	1
Simpson, ER	1
MacDonald, PC	1
Leblhuber, F	1
Neubauer, C	1
Peichl, M	1
Reisecker, F	1
Steinparz, FX	1
Windhager, E	1
Dienstl, E	1
Diamond, P	1
Candas, B	1
Sourla, A	1
Flamand, M	1
Robinzon, B	1
Cutolo, M	1
Nawata, H	1
Higuchi, K	1
Yanase, T	1
Takayanagi, R	1
Kato, K	1
Ibayashi, H	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Open-Label Vulvoscopy Photography Study of Changes in Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Administration of 6.5 Mg Vaginal Prasterone in Menopausal Women With Moderate to Severe Dyspareunia[NCT03568604]	Phase 4	18 participants (Actual)	Interventional	2018-08-07	Completed
Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study)[NCT03740945]	Phase 3	0 participants (Actual)	Interventional	2018-11-06	Withdrawn (stopped due to Business decision to not perform this study.)
A Randomized, Double-blind, Placebo-controlled Trial on the Preventive Effect of Intravaginal Prasterone (DHEA, Intrarosa®) on Recurrent Urinary Tract Infections in Women With Genitourinary Syndrome of Menopause[NCT03854396]	Phase 3	0 participants (Actual)	Interventional	2020-05-31	Withdrawn (stopped due to due to termination of ISR by PI with agreement by grant sponsor)
[NCT01358760]	Phase 3	450 participants (Actual)	Interventional	2011-06-30	Completed
DHEA Against Vaginal Atrophy - Safety Study of 12 Months[NCT01256671]	Phase 3	530 participants (Actual)	Interventional	2010-12-31	Completed
DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA)[NCT01256684]	Phase 3	255 participants (Actual)	Interventional	2010-12-31	Completed
Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)[NCT01846442]	Phase 3	218 participants (Actual)	Interventional	2007-06-30	Completed
[NCT02013544]	Phase 3	558 participants (Actual)	Interventional	2014-02-28	Completed
A Review on the Clinical Outcome of Chinese Women With Moderate to Severe Symptoms of Genitourinary Syndrome of Menopause (GSM) Treated With Vaginal Dehydroepiandrosterone (DHEA)[NCT05434351]		4 participants (Actual)	Observational	2022-08-01	Terminated (stopped due to inadequate sample and only few patients were prescribed with vaginal DHEA)
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)[NCT03619005]	Phase 3	0 participants (Actual)	Interventional	2018-11-13	Withdrawn (stopped due to Business decision to not continue this study (only few subjects were screened).)
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)[NCT03287232]	Phase 3	653 participants (Actual)	Interventional	2017-10-16	Completed
A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy[NCT03782480]	Phase 3	40 participants (Anticipated)	Interventional	2019-03-02	Recruiting
To Investigate the Effectiveness of Adjuvant Supplements Prior to in Vitro Fertilization Cycles[NCT05471453]		90 participants (Anticipated)	Interventional	2022-03-02	Recruiting
Effect of DHEA on Skin Aging - Placebo-Controlled and Randomized Phase III Study in Postmenopausal Women.[NCT00248989]	Phase 3	150 participants (Actual)	Interventional	2004-11-01	Completed
Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women[NCT00317148]	Phase 2/Phase 3	50 participants (Actual)	Interventional	2005-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Intervention	percentage of parabasal cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	56.74	39.23	-17.51
0.50% DHEA	59.54	33.02	-26.52
Placebo	60.66	62.22	1.56

The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Dyspareunia

Intervention	percentage of superficial cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	1.12	3.43	2.31
0.50% DHEA	0.93	3.58	2.66
Placebo	0.97	1.80	0.83

The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.58	1.48	-1.10
0.50% DHEA	2.60	1.54	-1.06
Placebo	2.56	1.78	-0.78

The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.37	1.10	-1.28
0.50% DHEA	2.35	1.13	-1.22
Placebo	2.38	1.27	-1.12

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.60	2.16	-0.45
0.50% DHEA	2.65	2.12	-0.53
Placebo	2.66	2.31	-0.35

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.19	1.74	-0.46
0.50% DHEA	2.19	1.69	-0.50
Placebo	2.32	1.94	-0.38

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.66	2.25	-0.40
0.50% DHEA	2.72	2.16	-0.56
Placebo	2.78	2.40	-0.38

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Vaginal pH

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.55	2.07	-0.48
0.50% DHEA	2.55	2.07	-0.48
Placebo	2.71	2.33	-0.38

A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Dyspareunia

Intervention	pH units (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	6.27	5.69	-0.58
0.50% DHEA	6.29	5.67	-0.62
Placebo	6.34	6.06	-0.28

The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Irritation/Itching

Intervention	units on a scale (Mean)
	Baseline: Subgroup MS	Week 52: Subgroup MS	Change from Baseline: Subgroup MS	Baseline: Subgroup MBS/MS	Week 52: Subgroup MBS/MS	Change from Baseline: Subgroup MBS/MS
0.50% DHEA	2.53	0.85	-1.68	2.57	0.87	-1.69

The severity of irritation/itching was evaluated by a questionnaire. The severity of irritation/itching recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Vaginal Dryness

Intervention	units on a scale (Mean)
	Baseline: Subgroup MS	Week 52: Subgroup MS	Change from Baseline: Subgroup MS	Baseline: Subgroup MBS/MS	Week 52: Subgroup MBS/MS	Change from Baseline: Subgroup MBS/MS
0.50% DHEA	2.10	0.60	-1.50	2.13	0.74	-1.39

The severity of vaginal dryness was evaluated by a questionnaire. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Parabasal Cells).

Intervention	units on a scale (Mean)
	Baseline: Subgroup MS	Week 52: Subgroup MS	Change from Baseline: Subgroup MS	Baseline: Subgroup MBS/MS	Week 52: Subgroup MBS/MS	Change from Baseline: Subgroup MBS/MS
0.50% DHEA	2.22	0.59	-1.63	2.19	0.67	-1.52

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Superficial Cells).

Intervention	percentage of parabasal cells (Mean)
	Baseline: Subgroup ALL	Week 52: Subgroup ALL	Change from Baseline: Subgroup ALL	Baseline: Subgroup VVA	Week 52: Subgroup VVA	Change from Baseline: Subgroup VVA
0.50% DHEA	55.49	12.81	-42.67	63.95	14.80	-49.14

The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Vaginal pH.

Intervention	percentage of superficial cells (Mean)
	Baseline: Subgroup ALL	Week 52: Subgroup ALL	Change from Baseline: Subgroup ALL	Baseline: Subgroup VVA	Week 52: Subgroup VVA	Change from Baseline: Subgroup VVA
0.50% DHEA	2.02	9.42	7.41	0.96	8.81	7.85

A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium

Intervention	pH (Mean)
	Baseline: Subgroup ALL	Week 52: Subgroup ALL	Change from Baseline: Subgroup ALL	Baseline: Subgroup VVA	Week 52: Subgroup VVA	Change from Baseline: Subgroup VVA
0.50% DHEA	6.23	5.09	-1.14	6.40	5.13	-1.27

The long-term safety of intravaginal prasterone has been evaluated on different parameters including the endometrium. For this purpose, endometrial biopsies were performed at screening and at the end of the study (52 weeks) or at discontinuation visit for women who were exposed to intravaginal DHEA (prasterone) for at least 12 weeks. At screening, the endometrium had to be atrophic/inactive for women to be enrolled in the study. Only the end-of-study data are presented. (NCT01256671)
Timeframe: Baseline and Week 52 (or discontinuation)

Long-term Safety of Intravaginal Prasterone (DHEA): Serum Steroid Levels

Intervention	Participants (Count of Participants)
	Endometrium: Atrophic/Inactive	Endometrium: No/Insufficient Tissue for Diagnosis
0.50% DHEA	421	36

The long-term safety of intravaginal prasterone has been evaluated on different parameters including the serum levels of DHEA and its metabolites. For this purpose, blood samples were collected at Baseline and different post-Baseline timepoints for the determination of serum steroid levels by a central laboratory using validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods. The serum levels of dehydroepiandrosterone (DHEA), estradiol (E2) and testosterone (TESTO) obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Intervention	pg/mL (Mean)
	DHEA: Baseline	DHEA: Week 52	DHEA: Change from Baseline	E2: Baseline	E2: Week 52	E2: Change from Baseline	TESTO: Baseline	TESTO: Week 52	TESTO: Change from Baseline
0.50% DHEA	2071.61	2997.25	925.65	6.05	4.46	-1.59	161.28	189.44	28.17

The percentage of parabasal cell was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including the basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Intervention	Percentage of parabasal cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	65.72	28.43	-37.29
0.50% DHEA	65.05	17.65	-47.40
Placebo	68.48	66.86	-1.62

The percentage of superficial cell was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including the basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

Intervention	Percentage of superficial cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	0.68	5.43	4.75
0.50% DHEA	0.68	6.30	5.62
Placebo	0.73	1.64	0.91

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.56	1.54	-1.01
0.50% DHEA	2.63	1.36	-1.27
Placebo	2.58	1.71	-0.87

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.94	2.27	-0.67
0.50% DHEA	2.94	2.05	-0.89
Placebo	2.82	2.56	-0.26

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.57	1.92	-0.65
0.50% DHEA	2.57	1.69	-0.88
Placebo	2.58	2.13	-0.45

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.90	2.32	-0.58
0.50% DHEA	2.89	2.14	-0.75
Placebo	2.91	2.57	-0.34

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Dryness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.81	2.10	-0.71
0.50% DHEA	2.83	1.95	-0.88
Placebo	2.78	2.36	-0.42

The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Vaginal pH

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.20	0.91	-1.29
0.50% DHEA	2.37	0.92	-1.45
Placebo	2.33	1.32	-1.02

Change From Baseline to Week 12 of Vaginal Color

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	6.48	5.70	-0.77
0.50% DHEA	6.47	5.43	-1.04
Placebo	6.51	6.31	-0.21

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 of Vaginal Epithelial Integrity

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	3.0	2.0	-1.0
0.50% DHEA	3.1	1.8	-1.3
1.00% DHEA	3.1	1.6	-1.5
Placebo	3.1	2.7	-0.5

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 of Vaginal Epithelial Surface Thickness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	2.7	1.7	-1.0
0.50% DHEA	2.8	1.5	-1.3
1.00% DHEA	2.7	1.4	-1.3
Placebo	2.8	2.4	-0.4

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial surface thickness(one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 of Vaginal Secretions

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	2.9	1.9	-1.0
0.50% DHEA	3.1	1.8	-1.3
1.00% DHEA	3.0	1.6	-1.4
Placebo	3.0	2.6	-0.4

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Co-primary Endpoint: Change From Baseline to Week 12 of Self-assessment of the Most Bothersome Symptom Dyspareunia

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	3.1	1.9	-1.2
0.50% DHEA	3.2	1.8	-1.4
1.00% DHEA	3.0	1.5	-1.4
Placebo	3.1	2.7	-0.4

The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Parabasal Cells)

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	2.8	1.4	-1.3
0.50% DHEA	2.7	1.1	-1.6
1.00% DHEA	2.6	1.2	-1.4
Placebo	2.8	2.3	-0.4

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Superficial Cells)

Intervention	percentage of parabasal cells (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	65.5	16.9	-48.6
0.50% DHEA	53.4	11.0	-42.4
1.00% DHEA	61.8	6.90	-54.9
Placebo	46.7	47.8	1.1

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal pH.

Intervention	percentage of superficial cells (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	0.4	5.7	5.3
0.50% DHEA	0.4	5.2	4.8
1.00% DHEA	0.4	6.5	6.1
Placebo	0.6	0.5	-0.1

A pH strip was applied directly to the lateral wall of the vagina using forceps. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Intervention	pH (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	6.6	5.5	-1.1
0.50% DHEA	6.6	5.2	-1.5
1.00% DHEA	6.5	5.1	-1.4
Placebo	6.5	6.0	-0.5

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Intervention	Percentage of parabasal cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	54.25	12.74	-41.51
Placebo	51.66	39.68	-11.98

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

Intervention	Percentage of superficial cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	1.02	11.22	10.20
Placebo	1.04	2.78	1.75

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.54	1.13	-1.42
Placebo	2.56	1.50	-1.06

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.75	2.03	-0.73
Placebo	2.67	2.34	-0.33

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.45	1.75	-0.69
Placebo	2.43	2.06	-0.37

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.83	2.09	-0.74
Placebo	2.76	2.41	-0.36

Change From Baseline to Week 12 in Severity of Vaginal Dryness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.70	1.97	-0.73
Placebo	2.63	2.24	-0.39

Change From Baseline to Week 12 in Vaginal pH

Article	Year
Current challenges in the pharmacological management of genitourinary syndrome of menopause. Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:1 Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of	2023
Current challenges in the pharmacological management of genitourinary syndrome of menopause. Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:1 Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of	2023
Current challenges in the pharmacological management of genitourinary syndrome of menopause. Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:1 Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of	2023
Current challenges in the pharmacological management of genitourinary syndrome of menopause. Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:1 Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of	2023
The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA. Climacteric : the journal of the International Menopause Society, 2023, Volume: 26, Issue:4 Topics: Administration, Intravaginal; Androgens; Atrophy; Dehydroepiandrosterone; Dyspareunia; Estrogens; Fe	2023
▼Prasterone for vulvar and vaginal atrophy. Drug and therapeutics bulletin, 2019, Volume: 57, Issue:12 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Female; Humans; Pessaries; Vaginal Di	2019
An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:4 Topics: Administration, Intravaginal; Androgens; Atrophy; Dehydroepiandrosterone; Dyspareunia; Estrogens; Fe	2020
The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy. Pharmacological research, 2021, Volume: 166 Topics: Animals; Atrophy; Dehydroepiandrosterone; Female; Humans; Postmenopause; Vagina; Vaginal Diseases; V	2021
Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2021, Volume: 37, Issue:8 Topics: Administration, Intravaginal; Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female;	2021
Genitourinary Syndrome of Menopause. Clinical obstetrics and gynecology, 2018, Volume: 61, Issue:3 Topics: Administration, Intravaginal; Administration, Oral; Atrophy; Dehydroepiandrosterone; Dyspareunia; Es	2018
Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. Climacteric : the journal of the International Menopause Society, 2019, Volume: 22, Issue:1 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Menopaus	2019
Treatment of vaginal atrophy. Women's health (London, England), 2014, Volume: 10, Issue:2 Topics: Administration, Cutaneous; Administration, Intravaginal; Administration, Oral; Androgens; Atrophic V	2014
Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. The Journal of steroid biochemistry and molecular biology, 2015, Volume: 145 Topics: Atrophy; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Hydrogen-Ion Concentration; Libido; Ov	2015
Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause (New York, N.Y.), 2017, Volume: 24, Issue:4 Topics: Androgens; Animals; Atrophy; Collagen; Dehydroepiandrosterone; Epithelium; Estrogens; Female; Humans	2017
Science of intracrinology in postmenopausal women. Menopause (New York, N.Y.), 2017, Volume: 24, Issue:6 Topics: Androgens; Atrophy; Dehydroepiandrosterone; Enzyme Inhibitors; Enzymes; Estrogens; Female; Humans; I	2017
Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology. The Journal of steroid biochemistry and molecular biology, 2017, Volume: 168 Topics: Androgens; Animals; Atrophy; Dehydroepiandrosterone; Estrogens; Female; Gonadal Steroid Hormones; Hu	2017
Vulvovaginal atrophy: current and future therapies (CME). The journal of sexual medicine, 2010, Volume: 7, Issue:3 Topics: Adjuvants, Immunologic; Aged; Atrophy; Dehydroepiandrosterone; Drug Administration Schedule; Drug Th	2010
Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas, 2011, Volume: 70, Issue:1 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Endometrium; Female; Humans; Randomiz	2011
Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause (New York, N.Y.), 2012, Volume: 19, Issue:1 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Breast Neoplasms; Complementa	2012
Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Rheumatology (Oxford, England), 1999, Volume: 38, Issue:6 Topics: Adjuvants, Immunologic; Atrophy; Autoimmunity; Dehydroepiandrosterone; Diabetes Mellitus; Female; Gl	1999

Article	Year
Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient? Post reproductive health, 2022, Volume: 28, Issue:4 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Menopaus	2022
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause (New York, N.Y.), 2017, Volume: 24, Issue:11 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Doubl	2017
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause (New York, N.Y.), 2017, Volume: 24, Issue:11 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Doubl	2017
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause (New York, N.Y.), 2017, Volume: 24, Issue:11 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Doubl	2017
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause (New York, N.Y.), 2017, Volume: 24, Issue:11 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Doubl	2017
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2018, Volume: 25, Issue:11 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehyd	2018
Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:4 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone;	2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 2015, Volume: 81, Issue:1 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 2015, Volume: 81, Issue:1 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 2015, Volume: 81, Issue:1 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 2015, Volume: 81, Issue:1 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.), 2015, Volume: 22, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Biopsy; Dehydroepiandrosterone; Endometrium; Fem	2015
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Coitu	2015
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Coitu	2015
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Coitu	2015
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Coitu	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:3 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Fem	2016
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:3 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Fem	2016
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:3 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Fem	2016
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:3 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Fem	2016
High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2010, Volume: 26, Issue:7 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Female; Humans;	2010
Effects of topical DHEA on aging skin: a pilot study. Maturitas, 2008, Feb-20, Volume: 59, Issue:2 Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind	2008
Age and sex differences of dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels in normal controls and Alzheimer's disease (AD). Psychopharmacology, 1993, Volume: 111, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Atrophy; Cerebral Cortex; Dehy	1993

Article	Year
Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause. Climacteric : the journal of the International Menopause Society, 2022, Volume: 25, Issue:3 Topics: Atrophy; Consensus; Dehydroepiandrosterone; Female; Female Urogenital Diseases; Humans; Menopause; S	2022
Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. Climacteric : the journal of the International Menopause Society, 2022, Volume: 25, Issue:5 Topics: Aromatase Inhibitors; Atrophy; Breast Neoplasms; Cancer Survivors; Dehydroepiandrosterone; Estradiol	2022
What is the role of dehydroepiandrosterone in gynecologic practice? JAAPA : official journal of the American Academy of Physician Assistants, 2019, Volume: 32, Issue:12 Topics: Administration, Intravaginal; Administration, Oral; Atrophy; Dehydroepiandrosterone; Dyspareunia; Fe	2019
Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study. European journal of obstetrics, gynecology, and reproductive biology, 2021, Volume: 263 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Female; Humans; Pilot Projects; Postm	2021
Dehydroepiandrosterone use in postmenopausal women: an androgenic option for managing sexual pain caused by vulvovaginal atrophy. Menopause (New York, N.Y.), 2017, Volume: 24, Issue:11 Topics: Atrophy; Dehydroepiandrosterone; Female; Humans; Menopause; Pain; Postmenopause	2017
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause (New York, N.Y.), 2018, Volume: 25, Issue:7 Topics: Administration, Intravaginal; Aged; Androgens; Atrophy; Consensus; Dehydroepiandrosterone; Dyspareun	2018
Prasterone: A Review in Vulvovaginal Atrophy. Drugs & aging, 2019, Volume: 36, Issue:8 Topics: Administration, Intravaginal; Atrophy; Clinical Trials, Phase III as Topic; Dehydroepiandrosterone;	2019
Newer Name, Newer Treatments: The Genitourinary Syndrome of Menopause. Journal of women's health (2002), 2019, Volume: 28, Issue:7 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Estrogens; Fe	2019
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. The Journal of steroid biochemistry and molecular biology, 2016, Volume: 159 Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehydroepiandrosterone; Estra	2016
Potential prevention by oral DHEA of superficial tears in elderly atrophic skin. The Journal of steroid biochemistry and molecular biology, 2017, Volume: 171 Topics: Aged; Aged, 80 and over; Aging; Atrophy; Clinical Trials as Topic; Dehydration; Dehydroepiandrostero	2017
Consultation corner. The latest on female sexual health. The Johns Hopkins medical letter health after 50, 2010, Volume: 22, Issue:9 Topics: Adjuvants, Immunologic; Adult; Antidepressive Agents, Second-Generation; Atrophy; Benzimidazoles; Bu	2010
T cells affect thymic involution during puberty by inducing regression of the adrenal reticularis. The journal of physiological sciences : JPS, 2012, Volume: 62, Issue:3 Topics: Animals; Antibodies, Monoclonal; Atrophy; CD3 Complex; CD4-Positive T-Lymphocytes; Dehydroepiandrost	2012
[The mechanism of skeletal muscle aging]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2004, Volume: 41, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aging; Atrophy; Dehydroepiandrosterone; Humans; Insulin-Like Growth	2004
Hypercholesterolemia due to elevated low density lipoprotein-cholesterol in newborns with anencephaly and adrenal atrophy. The Journal of clinical endocrinology and metabolism, 1983, Volume: 57, Issue:1 Topics: Adrenal Glands; Anencephaly; Atrophy; Cholesterol; Cholesterol, LDL; Dehydroepiandrosterone; Female;	1983
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:10 Topics: Aged; Atrophy; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Dehydroep	1997
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:10 Topics: Aged; Atrophy; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Dehydroep	1997
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:10 Topics: Aged; Atrophy; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Dehydroep	1997
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:10 Topics: Aged; Atrophy; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Dehydroep	1997
Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat. The Journal of steroid biochemistry and molecular biology, 1998, Volume: 66, Issue:3 Topics: Administration, Intravaginal; Animals; Atrophy; Cell Division; Dehydroepiandrosterone; Endometrium;	1998
Mechanism of dissociation of cortisol and adrenal androgen secretion after removal of adrenocortical adenoma in patients with Cushing's syndrome. Endocrinologia japonica, 1985, Volume: 32, Issue:5 Topics: Adenoma; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenal Glands; Adult; Atrophy; Cells, Cultured;	1985

dehydroepiandrosterone and Atrophy

Research Excerpts

Research

Studies (46)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Severity of Dyspareunia

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Change From Baseline to Week 12 in Vaginal pH

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Dyspareunia

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Irritation/Itching

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Vaginal Dryness

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Parabasal Cells).

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Superficial Cells).

Change From Baseline to Week 52 of Vaginal pH.

Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium

Long-term Safety of Intravaginal Prasterone (DHEA): Serum Steroid Levels

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Change From Baseline to Week 12 in Severity of Vaginal Dryness

Change From Baseline to Week 12 in Vaginal pH

Change From Baseline to Week 12 of Vaginal Color

Change From Baseline to Week 12 of Vaginal Epithelial Integrity

Change From Baseline to Week 12 of Vaginal Epithelial Surface Thickness

Change From Baseline to Week 12 of Vaginal Secretions

Co-primary Endpoint: Change From Baseline to Week 12 of Self-assessment of the Most Bothersome Symptom Dyspareunia

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Parabasal Cells)

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Superficial Cells)

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal pH.

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Change From Baseline to Week 12 in Severity of Vaginal Dryness

Change From Baseline to Week 12 in Vaginal pH

Reviews

Trials

Other Studies